<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.4//EN" "ep-patent-document-v1-4.dtd">
<ep-patent-document id="EP09830560A9W1" file="EP09830560W1A9.xml" lang="en" country="EP" doc-number="2374869" kind="A9" correction-code="W1" date-publ="20120404" status="c" dtd-version="ep-patent-document-v1-4">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORS..SM..................</B001EP><B005EP>J</B005EP><B007EP>DIM360 Ver 2.15 (14 Jul 2008) -  1999001/0</B007EP></eptags></B000><B100><B110>2374869</B110><B120><B121>CORRECTED EUROPEAN PATENT APPLICATION</B121><B121EP>published in accordance with Art. 153(4) EPC</B121EP></B120><B130>A9</B130><B132EP>A2</B132EP><B140><date>20120404</date></B140><B150><B151>W1</B151><B155><B1551>de</B1551><B1552>Beschreibung</B1552><B1551>en</B1551><B1552>Description</B1552><B1551>fr</B1551><B1552>Description</B1552></B155></B150><B190>EP</B190></B100><B200><B210>09830560.0</B210><B220><date>20091201</date></B220><B240><B241><date>20110702</date></B241></B240><B250>ko</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>20080120899</B310><B320><date>20081202</date></B320><B330><ctry>KR</ctry></B330></B300><B400><B405><date>20120404</date><bnum>201214</bnum></B405><B430><date>20111012</date><bnum>201141</bnum></B430><B480><date>20120404</date><bnum>201214</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>C12N   1/20        20060101AFI20100624BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>C12N   1/00        20060101ALI20100624BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>WIRKSAME PFLANZENSCHÄDLINGSBEKÄMPFUNG MIT PSEUDOMONAS OLEOVORANS-STÄMMEN</B542><B541>en</B541><B542>EFFECTIVE CONTROL OF VIRAL PLANT DISEASE WITH STRAINS OF PSEUDOMONAS OLEOVORANS</B542><B541>fr</B541><B542>LUTTE EFFICACE CONTRE UNE MALADIE VIRALE DES PLANTES AVEC DES SOUCHES DE PSEUDOMONAS OLEOVORANS</B542></B540><B590><B598>9</B598></B590></B500><B700><B710><B711><snm>Lee, Yong Jin</snm><iid>101185598</iid><irf>463.109537</irf><adr><str>Hyundai Supervill A-3403 
1446-11 Seocho-dong 
Seocho-gu</str><city>Seoul 137-070</city><ctry>KR</ctry></adr></B711></B710><B720><B721><snm>HWANG, In Cheon</snm><adr><str>Sambo Apt. 
107-203 Hwangseong-dong</str><city>Gyeongju-si
Gyeongsangbuk-do 780-130</city><ctry>KR</ctry></adr></B721><B721><snm>JANG, Cheol</snm><adr><str>Hyundai Apt. 
203-401 Hwangseong-dong</str><city>Gyeongju-si
Gyeongsangbuk-do 780-130</city><ctry>KR</ctry></adr></B721><B721><snm>KIM, Nam Gyu</snm><adr><str>90 O-dong
Dong-gu</str><city>Daejeon 300-430</city><ctry>KR</ctry></adr></B721><B721><snm>KIM, Hyeong Min</snm><adr><str>23-1 Bukbu-dong</str><city>Gyeongju-si
Gyeongsangbuk-do 780-050</city><ctry>KR</ctry></adr></B721><B721><snm>LEE, Yong Jin</snm><adr><str>Hyundai Supervill A-3403
1446-11 Seocho-dong
Seocho-gu</str><city>Seoul 137-070</city><ctry>KR</ctry></adr></B721><B721><snm>LEE, Byung Man</snm><adr><str>Raemian Firstige 124-2801,
18-1, Banpo-dong, Socho-gu</str><city>Seoul 137-764</city><ctry>KR</ctry></adr></B721></B720><B740><B741><snm>Rowe, Daniel</snm><iid>100964114</iid><adr><str>Dehns 
St Bride's House 
10 Salisbury Square</str><city>London
EC4Y 8JD</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B860><B861><dnum><anum>KR2009007098</anum></dnum><date>20091201</date></B861><B862>ko</B862></B860><B870><B871><dnum><pnum>WO2010064822</pnum></dnum><date>20100610</date><bnum>201023</bnum></B871></B870></B800></SDOBI>
<abstract id="abst" lang="en">
<p id="pa01" num="0001">A strain of <i>Pseudomonas oleovorans</i> having a controlling activity against plant viral diseases and a microbial agent comprising the same are provided; and the microbial agent exhibits excellent protection against plant viral infections by Tobamovirus, Potyvirus, Tenuivirus, Cucumovirus and Begomovirus.
<img id="iaf01" file="imgaf001.tif" wi="81" he="51" img-content="drawing" img-format="tif"/></p>
</abstract><!-- EPO <DP n="1"> -->
<description id="desc" lang="en">
<heading id="h0001"><b><u>FIELD OF THE INVENTION</u></b></heading>
<p id="p0001" num="0001">The present invention relates to a <i>Pseudomonas oleovorans</i> strain having a controlling activity against plant viral diseases; and a microbial agent for controlling plant viral diseases comprising the same.</p>
<heading id="h0002"><b><u>BACKGROUND OF THE INVENTION</u></b></heading>
<p id="p0002" num="0002">Total cultivation area of garden crops has been increasing every year, however, various plant viral diseases have been occurred in most of the garden crops, resulting in serious economic damage.</p>
<p id="p0003" num="0003">The plant viruses damaging to the garden crops include Cucumber mosaic virus (CMV), Tobacco mosaic virus (TMV) and Potato virus Y (PVY). In order to control these viruses, agronomical controlling methods such as those using disease-free seeds and breeding novel cultivars resistant to the viruses have been developed, but the effects thereby are insignificant.</p>
<p id="p0004" num="0004">Meanwhile, transgenic plants resistant to the viruses have been developed by introducing a gene, such as a coat protein gene, a replication-associated gene, a satellite RNA gene and an antisense gene into the plants, but it will take for more time to achieve an industrial success (<nplcit id="ncit0001" npl-type="s"><text>Fitchen, J. H. and Beachy, R. N., Annu. Rev. Microbiol., 47:739-763, 1993</text></nplcit>).</p>
<p id="p0005" num="0005">Recently, there have been many studies to develop novel microbial agents using microorganisms for controlling the plant viruses. Especially, the microbial agents are environmental-friendly means which is capable of preserving natural ecosystem and has no mammalian toxicity and, therefore, demand for the microbial agents is increasing.<!-- EPO <DP n="2"> --></p>
<heading id="h0003"><b><u>SUMMARY OF THE INVENTION</u></b></heading>
<p id="p0006" num="0006">Accordingly, it is an object of the present invention to provide a microorganism effective in controlling plant viral diseases; and a microbial agent comprising the same.</p>
<p id="p0007" num="0007">In accordance with the above object, the present invention provides <i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) having a controlling activity against plant viral diseases; a culture thereof; a dried powder of the culture; and a microbial agent for controlling plant viral diseases comprising the strain, a culture thereof, or a dried powder of the culture as an active ingredient.</p>
<heading id="h0004"><b><u>BRIEF DESCRIPTION OF THE DRAWINGS</u></b></heading>
<p id="p0008" num="0008">The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, which respectively show:
<ul id="ul0001" list-style="none" compact="compact">
<li><figref idref="f0001">Fig. 1</figref>: the phylogenetic tree of the KBPF-004 strain;</li>
<li><figref idref="f0002">Fig. 2</figref>: the controlling activity of the 1,000-fold dilution of the KBPF-004 25% wettable powder (WP) against tobacco mosaic virus;</li>
<li><figref idref="f0002">Fig. 3</figref>: the inhibiting effect of the KBPF-004 25% WP against tobacco mosaic virus confirmed by RT-PCR;</li>
<li><figref idref="f0003">Fig. 4</figref>: the inhibiting effect of the KBPF-004 25% WP against the single- or multiple-infection of viruses confirmed by RT-PCR (C: Chungyang red pepper; D: Daemyung pepper; M: size marker; H: healthy plant; N: non-treated group; and 1, 2: KBPF-004-treated groups);</li>
<li><figref idref="f0004">Fig. 5</figref>: the photography of the virus particles treated with KBPF-004 25% WP confirmed by electron microscopy (TMV: Tobacco mosaic virus and PVY: Potato virus Y);</li>
<li><figref idref="f0004">Fig. 6</figref>: the infection inhibiting effect of KBPF-004 25% WP against the tobacco mosaic virus;</li>
<li><figref idref="f0005">Fig. 7</figref>: the controlling effect of the KBPF-004 25% WP against the pepper<!-- EPO <DP n="3"> --> mottle virus;</li>
<li><figref idref="f0006">Fig. 8</figref>: the controlling effect of the KBPF-004 25% WP against the rice stripe virus (A: non-treated group; and B: 500-fold diluted KBPF-004 25% WP-treated group);</li>
<li><figref idref="f0006">Fig. 9</figref>: the controlling effect of the KBPF-004 2.5% granules against the tobacco mosaic virus; and</li>
<li><figref idref="f0007">Fig. 10</figref>: the controlling effect of the KBPF-004 70% aqueous suspensions (AS) against the Tomato yellow leaf curl virus (A: non-treated (the commercial insecticide-treated group); and B: the 500-fold dilution of KBPF-004 70% aqueous suspensions and the commercial insecticide-treated group).</li>
</ul></p>
<heading id="h0005"><b><u>DETAILED DESCRIPTION OF THE INVENTION</u></b></heading>
<p id="p0009" num="0009">The present invention provides <i>Pseudomonas oleovorans</i> strain KBPF-004 (KCTC 10159BP) having a controlling activity against plant viral diseases.</p>
<p id="p0010" num="0010"><i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) forms yellow round colonies having pectinated stripes in the outline. The strain is shaped like a rod of 2∼3 µm in length and 0.3∼0.5 µm in width, and has a single long flagellum.</p>
<p id="p0011" num="0011">The inventive strain has 16S rDNA of 1,479 bp nucleotide sequence represented by SEQ ID NO: 1, which has 99.05% sequence homology to that of <i>Pseudomonas oleovorans</i> IAM 1508T. The taxonomic position of the inventive strain was investigated by constructing a phylogenetic tree (<figref idref="f0001">Fig. 1</figref>) according to Clustal method (<nplcit id="ncit0002" npl-type="s"><text>Thompson JD et al., Nuc. Acid. Res. 25: 4876-82, 1997</text></nplcit>).</p>
<p id="p0012" num="0012">The inventive strain is different from the existing <i>Pseudomonas oleovorans</i> strains in terms of its specific anti-viral activities.</p>
<p id="p0013" num="0013">Therefore, the strain was designated as <i>Pseudomonas oleovorans</i> KBPF-004, and deposited on January 11, 2002 at Korean Collection for Type Cultures (KCTC) under the accession number of KCTC 10159BP.</p>
<p id="p0014" num="0014">The present invention also provides a culture of <i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) effective in controlling plant viral diseases.<!-- EPO <DP n="4"> --></p>
<p id="p0015" num="0015">The culture may be prepared by inoculating <i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) cells onto a medium and subjecting them to a fermentation.</p>
<p id="p0016" num="0016">The medium may comprise conventional ingredients of a medium for culturing gram negative bacteria without any limitation. Preferably, the medium may comprise 1 g to 20 g of glucose, 1 g to 30 g of yeast extract, 0.1 g to 1 g of magnesium sulfate, 0.5 g to 5 g of potassium dihydrogen phosphate and 0.5 g to 5 g of potassium monohydrogen phosphate based on 1 ℓ of water. More preferably, the medium may comprise 7 g to 14 g of glucose, 15 g to 25 g of yeast extract, 0.1 g to 0.2 g of magnesium sulfate, 1 g to 2 g of potassium dihydrogen phosphate and 1 g to 2 g of potassium monohydrogen phosphate based on 1 ℓ of water.</p>
<p id="p0017" num="0017">The fermentation may be conducted at a temperature of 20 °C to 40 °C, preferably, 26 °C to 34 °C, with an aeration rate of 50 ℓ/min to 200 ℓ/min, preferably, 100 ℓ/min to 120 ℓ/min, and a rotation speed of 100 rpm to 250 rpm, preferably 120 rpm to 200 rpm. In order to prepare the inventive microbial agent, it is preferred to employ both strain cells and culture filtrates.</p>
<p id="p0018" num="0018">Further, the present invention provides a dried powder of the culture.</p>
<p id="p0019" num="0019">The dried powder may be prepared by the steps of sterilization, concentration and pulverization (freeze drying and milling).</p>
<p id="p0020" num="0020">The sterilization step may be conducted by heating the cell culture, upon completion of culturing, at a temperature of 80 °C to 120 °C for 1 to 20 min, preferably, at 90 °C to 100°C for 5 to 10 min.</p>
<p id="p0021" num="0021">The concentration step may be conducted by concentrating the sterilized culture under a reduced pressure at a temperature of 40 °C to 80 °C for 12 to 48 hours, preferably, at 65 °C to 75 °C for 24 to 36 hours.</p>
<p id="p0022" num="0022">The pulverization step may be conducted, but are not limited to, by subjecting the concentrated culture to drying process by freeze drying or spray-drying, and them to milling to prepare a powdered culture.</p>
<p id="p0023" num="0023">The freeze drying process may be conducted by drying the concentrated culture with sequentially rising a temperature starting from -80 °C for 48 to 96 hours, preferably, 60 to 80 hours.<!-- EPO <DP n="5"> --></p>
<p id="p0024" num="0024">The milling process is conducted by grinding the resulting freeze-dried products using a pin mill grinder to have particle sizes of 2 mm or below.</p>
<p id="p0025" num="0025">A microbial agent may be prepared by formulating the cells, the culture or the dried powder of the culture in combination with surfactants, nutrients, and carriers.</p>
<p id="p0026" num="0026">In addition, the present invention provides a microbial agent for controlling plant viral diseases comprising <i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) cells, a culture thereof, or a dried powder of the culture as an active ingredient.</p>
<p id="p0027" num="0027">The microbial agent for controlling plant viral diseases exhibits an anti-viral activity depending on the concentration of the active ingredient.</p>
<p id="p0028" num="0028">The microbial agent of the present invention may comprise 2.5 to 70% by weight of <i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) cells, the culture thereof, or the dried powder of the culture; 2 to 30% by weight of a surfactant; and a residual amount of a carrier. Preferably, the microbial agent of the present invention may comprise 2.5 to 70% by weight of <i>Pseudomonas oleovorans</i> KBPF-004 (KCTC 10159BP) cells, the culture thereof, or the dried powder of the culture.</p>
<p id="p0029" num="0029">The surfactants may include an anionic surfactant, a nonionic surfactant, or a mixture thereof. The surfactants may be selected from the group consisting of sodium or calcium salts of sulfonate compounds such as C<sub>8∼12</sub> alkylaryl sulfonate, C<sub>8∼12</sub> dialkylaryl sulfonate, C<sub>8∼12</sub> dialkyl sulfosuccinate, lignin sulfonate, naphthalene sulfonate condensates, naphthalene sulfonate formalin condensates, C<sub>8∼12</sub> alkyl naphthalene sulfonate formalin condensates and polyoxyethylene C<sub>8∼12</sub> alkylphenyl sulfonate; sodium or calcium salts of sulfate compounds such as C<sub>8∼12</sub>alkyl sulfate, C<sub>8∼12</sub> alkyl aryl sulfate, polyoxyethylene C<sub>8∼12</sub> alkyl sulfate and polyoxyethylene C<sub>8∼12</sub> alkylphenyl sulfate; sodium or calcium salts of succinate compounds such as polyoxyalkylene succinate; anionic surfactants such as sodium benzoate and alkyl carboxylate; nonionic surfactants such as polyoxyethylene C<sub>12∼8</sub> alkyl ether, polyoxyethylene C<sub>8∼12</sub> alkylphenyl ether,<!-- EPO <DP n="6"> --> polyoxyethylene C<sub>8∼12</sub> alkylphenyl polymers and ethyleneoxide propyleneoxide copolymers; polycarboxylate; Triton<sup>®</sup> 100; Tween<sup>®</sup> 80; and a mixture thereof, but are not limited thereto.</p>
<p id="p0030" num="0030">The carriers may be selected from the group consisting of bentonite, talc, clay, kaolin, calcium carbonate, silica, pumice stone, diatomaceous earth, acidic white bole, zeolite, perlite, white carbon, ammonium sulfate, urea, glucose, dextrin, water, and a mixture thereof, but are not limited thereto.</p>
<p id="p0031" num="0031">Also, the microbial agent of the present invention may be formulated by using the surfactants and/or carriers in a form selected from the group consisting of wettable powders (WP), water dispersible granules (WG), suspension concentrates (SC), granules, aqueous suspensions (AS), soluble powders (SP), water soluble granules (SG), capsules.</p>
<p id="p0032" num="0032">In the present invention, the cells or the culture may be supplied in the form of the microbial agent for controlling plant viral diseases comprising the same, or in a separate storage form for a long-term storage and for mixing with other ingredients before use. For long-term storage, the cells or cultures may be stored in a glycerol storage solution at below -70 °C , or in a freeze-dried form.</p>
<p id="p0033" num="0033">The wettable powder, a form of the microbial agent provided in the present invention, may be prepared by obtaining a dried powder of the culture by a post-treatment process; adding the surfactants, nutrients and carriers thereto; and mixing them.</p>
<p id="p0034" num="0034">The granules, a form of the microbial agent provided in the present invention, may be prepared by obtaining a dried powder of the culture by a post-treatment process; adding the surfactants, carriers and disintegrating agents thereto; and mixing them. The disintegrating agent useful in the present invention may be selected from the group consisting of bentonite, talc, dialite, kaolin, calcium carbonate and a mixture thereof.</p>
<p id="p0035" num="0035">The granules may further comprise an ingredient selected from the group consisting of surface active agents, inactive carriers, preservatives, wetting agents, supply-promoting agents, attracting agents, encapsulants, binders, emulsifiers, dyes, UV protectors, buffering agents or flow agents, in addition to the microbial<!-- EPO <DP n="7"> --> cells and/or the fermentation products (the culture of the microorganism).</p>
<p id="p0036" num="0036">The aqueous suspensions, a form of the microbial agent provided in the present invention, may be prepared by sterile-concentrating the culture by a post-treatment process; adding an ingredient selected from the group consisting of the surfactants, preservatives, wetting agents, supply-promoting agents, attracting agents, UV protectors and buffering agents thereto; and mixing them.</p>
<p id="p0037" num="0037">The microbial agent of the present invention is effective in controlling most of the plant viral diseases caused by pathogenic virus groups, such as Allexivirus, Alfamovirus, Ampelovirus, Bymovirus, Begomovirus, Capillovirus, Carlavirus, Carmovirus, Caulimovirus, Closterovirus, Comovirus, Cucumovirus, Crinivirus, Cytorhabdovirus, Fabavirus, Flexiviridae, Foveavirus, Furovirus, Geminivirus, Hordeivirus, Ilarvirus, Luteovirus, Maculavirus, Nepovirus, Potexvirus, Potyvirus, Phytoreovirus, Polerovirus, Pomovirus, Sadwavirus, Taastrupvirus, Tenuivirus, Tobamovirus, Tobravirus, Tombusvirus, Tospovirus, Trichovirus, and a combination thereof. Especially, the inventive microbial agent is very effective in controlling Tobamovirus, Potyvirus and Tenuivirus groups composed of bar-shaped (thread-shaped) single stranded RNA, Cucumovirus group composed of circular single stranded RNA and Begomovirus group composed of circular single stranded DNA.</p>
<p id="p0038" num="0038">More specifically, the microbial agent of the present invention presents an excellent controlling effect on Pepper mottle virus (PepMoV), Pepper mild mottle virus (PMMoV), Cucumber mosaic virus (CMV), Tomato yellow leaf curl virus (TYLCV), Cucumber green mottle mosaic virus (CGMMV), Potato virus Y (PVY), Zucchini yellow mosaic virus (ZYMV), Turnip mosaic virus (TuMV), or Rice stripe virus (RSV) and the like.</p>
<p id="p0039" num="0039">The following Examples are intended to further illustrate the present invention without limiting its scope.</p>
<heading id="h0006"><b>Example 1: Isolation and identification of KBPF-004</b></heading><!-- EPO <DP n="8"> -->
<heading id="h0007"><u>&lt;1-1&gt; Isolation of KBPF-004 strain</u></heading>
<p id="p0040" num="0040">Soil samples comprising tobacco plant roots were collected from the tobacco fields located in eumsung-gun of chungcheongbuk-do. The collected soil sample was diluted with sterile distilled water, and the dilution was spread onto a TSA agar medium (Difco, Detroit, MI) supplemented with 100 ppm cyclohexamide and incubated at 27 °C to isolate a pure culture of a strain.</p>
<heading id="h0008"><u>&lt;1-2&gt; Identification of KBPF-004 strain</u></heading>
<p id="p0041" num="0041">The strain isolated in Example &lt;1-1&gt; was incubated in a Mueller Hinton medium comprising 2.0 g of beef extract, 17.5 g of casein, 1.5 g of starch and 17.5 g of agar at 30 °C for 24 hours.</p>
<p id="p0042" num="0042">Yellow round colonies of the isolated strain were formed, which had pectinated stripes in the outline. The strain was shaped like a rod of 2∼3 µm in length and 0.3∼0.5 µm in width, and had a single long flagellum. In order to identify biochemical features of the strain, fatty acid composition analysis, Biolog GN microplate analysis and API20NE analysis were conducted, and the results are shown in Tables 1 to 3, respectively.
<tables id="tabl0001" num="0001">
<table frame="all">
<title>&lt;Table 1&gt;</title>
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="36mm"/>
<colspec colnum="2" colname="col2" colwidth="22mm"/>
<thead>
<row>
<entry align="center" valign="top">Fatty acid composition</entry>
<entry align="center" valign="top">Content (%)</entry></row></thead>
<tbody>
<row>
<entry align="center">C<sub>10:0</sub>3-OH</entry>
<entry align="center">2.19</entry></row>
<row>
<entry align="center">C<sub>12:0</sub></entry>
<entry align="center">5.14</entry></row>
<row>
<entry align="center">C<sub>12:0</sub> 2-OH</entry>
<entry align="center">2.70</entry></row>
<row>
<entry align="center">C<sub>12:0</sub>3-OH</entry>
<entry align="center">3.79</entry></row>
<row>
<entry align="center">C<sub>16:1</sub> w7c/<sub>15:0</sub>iso 2-OH</entry>
<entry align="center">18.74</entry></row>
<row>
<entry align="center">C<sub>16:0</sub></entry>
<entry align="center">20.45</entry></row>
<row>
<entry align="center">C<sub>18:1</sub> w7c</entry>
<entry align="center">45.88</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="9"> -->
<tables id="tabl0002" num="0002">
<table frame="all">
<title>&lt;Table 2&gt;</title>
<tgroup cols="6">
<colspec colnum="1" colname="col1" colwidth="26mm"/>
<colspec colnum="2" colname="col2" colwidth="29mm"/>
<colspec colnum="3" colname="col3" colwidth="29mm"/>
<colspec colnum="4" colname="col4" colwidth="28mm"/>
<colspec colnum="5" colname="col5" colwidth="28mm"/>
<colspec colnum="6" colname="col6" colwidth="28mm"/>
<tbody>
<row>
<entry align="center" valign="middle">-<br/>
Water</entry>
<entry align="center" valign="middle">-<br/>
α-cyclodextrin</entry>
<entry align="center" valign="middle">-<br/>
Detrin</entry>
<entry align="center" valign="middle">-<br/>
glycogen</entry>
<entry align="center" valign="middle">-<br/>
Tween 40</entry>
<entry align="center" valign="middle">-<br/>
Tween 80</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
i-erythritol</entry>
<entry align="center" valign="middle">+<br/>
D-fructose</entry>
<entry align="center" valign="middle">+<br/>
L-fucose</entry>
<entry align="center" valign="middle">+<br/>
D-galactose</entry>
<entry align="center" valign="middle">-<br/>
gentiobiose</entry>
<entry align="center" valign="middle">+<br/>
D-glucose</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
D-melibiose</entry>
<entry align="center" valign="middle">-<br/>
β-methyl-D glucoside</entry>
<entry align="center" valign="middle">-<br/>
D-psicose</entry>
<entry align="center" valign="middle">-<br/>
D-raffinose</entry>
<entry align="center" valign="middle">-<br/>
L-rhamnose</entry>
<entry align="center" valign="middle">+<br/>
D-sorbitol</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
Acetic acid</entry>
<entry align="center" valign="middle">+<br/>
Cis-aconitic acid</entry>
<entry align="center" valign="middle">+<br/>
Citric acid</entry>
<entry align="center" valign="middle">-<br/>
Fomic acid</entry>
<entry align="center" valign="middle">+<br/>
D-galactonic acid lactone</entry>
<entry align="center" valign="middle">+<br/>
D-galacturonic acid</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
p-hydroxy phenylacetic acid</entry>
<entry align="center" valign="middle">v<br/>
Itaconic aicd</entry>
<entry align="center" valign="middle">-<br/>
α-keto butyric acid</entry>
<entry align="center" valign="middle">+<br/>
α-keto glutamic acid</entry>
<entry align="center" valign="middle">-<br/>
α-keto valeric acid</entry>
<entry align="center" valign="middle">+<br/>
D,L-lactic acid</entry></row>
<row>
<entry align="center" valign="middle">+<br/>
Bromo succinic acid</entry>
<entry align="center" valign="middle">-<br/>
Succinamic acid</entry>
<entry align="center" valign="middle">-<br/>
Glucuron amide</entry>
<entry align="center" valign="middle">-<br/>
Alaninamide</entry>
<entry align="center" valign="middle">-<br/>
v D-alanine</entry>
<entry align="center" valign="middle">+<br/>
L-alanine</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
L-histidine</entry>
<entry align="center" valign="middle">-<br/>
Hydroxy L-proline</entry>
<entry align="center" valign="middle">-<br/>
L-leucine</entry>
<entry align="center" valign="middle">-<br/>
L-omithine</entry>
<entry align="center" valign="middle">-<br/>
L-pheyl alanine</entry>
<entry align="center" valign="middle">+<br/>
L-proline</entry></row>
<row>
<entry align="center" valign="middle">v<br/>
Urocanic acid</entry>
<entry align="center" valign="middle">-<br/>
Inosine</entry>
<entry align="center" valign="middle">-<br/>
Uridine</entry>
<entry align="center" valign="middle">-<br/>
Thymidine</entry>
<entry align="center" valign="middle">-<br/>
Phenyl ethylamine</entry>
<entry align="center" valign="middle">-<br/>
Putrlscine</entry></row>
<row>
<entry align="center" valign="middle">- N-acetyl-D-galactosamine</entry>
<entry align="center" valign="middle">- N-acetyl-D-glucosamine</entry>
<entry align="center" valign="middle">-<br/>
Adonitol</entry>
<entry align="center" valign="middle">-<br/>
L-arabinose</entry>
<entry align="center" valign="middle">-<br/>
D-arabitol</entry>
<entry align="center" valign="middle">-<br/>
cellobiose</entry></row>
<row>
<entry align="center" valign="middle">+<br/>
m-inositol</entry>
<entry align="center" valign="middle">-<br/>
D-lactose</entry>
<entry align="center" valign="middle">-<br/>
Lactulose</entry>
<entry align="center" valign="middle">-<br/>
Maltose</entry>
<entry align="center" valign="middle">+<br/>
Mannitol</entry>
<entry align="center" valign="middle">+<br/>
D-mannose</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
Sucrose</entry>
<entry align="center" valign="middle">+<br/>
D-trehalose</entry>
<entry align="center" valign="middle">-<br/>
Turanose</entry>
<entry align="center" valign="middle">-<br/>
Xylitol</entry>
<entry align="center" valign="middle">+<br/>
Methyl pyruvate</entry>
<entry align="center" valign="middle">+<br/>
Mono-methyl succinate</entry></row>
<row>
<entry align="center" valign="middle">+<br/>
D-gluconic acid</entry>
<entry align="center" valign="middle">+<br/>
D-glucosaminic acid</entry>
<entry align="center" valign="middle">+<br/>
D-glucuronic acid</entry>
<entry align="center" valign="middle">- α-hydroxy-butyric acid</entry>
<entry align="center" valign="middle">+ β-hydroxy-butyric acid</entry>
<entry align="center" valign="middle">- vγ-hydroxy-butyric acid</entry></row>
<row>
<entry align="center" valign="middle">v<br/>
Malonic acid</entry>
<entry align="center" valign="middle">-<br/>
Propioic acid</entry>
<entry align="center" valign="middle">+<br/>
Quinic acid</entry>
<entry align="center" valign="middle">+<br/>
vD-acid saccharicenyl</entry>
<entry align="center" valign="middle">-<br/>
Sebacicc acid</entry>
<entry align="center" valign="middle">+<br/>
Succinic acid</entry></row>
<row>
<entry align="center" valign="middle">-<br/>
L-alanyl-glycine</entry>
<entry align="center" valign="middle">+<br/>
L-asparagine</entry>
<entry align="center" valign="middle">+<br/>
L-aspartic acid</entry>
<entry align="center" valign="middle">+<br/>
L-glutamic acid</entry>
<entry align="center" valign="middle">- Glycyl-L-asparatic acid</entry>
<entry align="center" valign="middle">-<br/>
Glycyl-L-glutamic acid</entry></row>
<row>
<entry align="center" valign="middle">+<br/>
L-pyroglutamic acid</entry>
<entry align="center" valign="middle">-<br/>
D-serine</entry>
<entry align="center" valign="middle">+<br/>
L-serine</entry>
<entry align="center" valign="middle">-<br/>
L-threonine</entry>
<entry align="center" valign="middle">v<br/>
D,L-camitine</entry>
<entry align="center" valign="middle">-<br/>
γ-amino gutyric acid</entry></row><!-- EPO <DP n="10"> -->
<row>
<entry align="center" valign="middle">-<br/>
2-amino ethanol</entry>
<entry align="center" valign="middle">-<br/>
2,3-butanediol</entry>
<entry align="center" valign="middle">+<br/>
Glycerol</entry>
<entry align="center" valign="middle">-<br/>
D,L-glycerol phosphate</entry>
<entry align="center" valign="middle">-<br/>
Glucose-1-phosphate</entry>
<entry align="center" valign="middle">-<br/>
Glucose-6-phosphate</entry></row>
<row rowsep="0">
<entry namest="col1" nameend="col6" align="center" valign="middle">Degree of reaction</entry></row>
<row>
<entry namest="col1" nameend="col6" align="center" valign="middle">+: at least 80%; -: at most 20%; v: 21-79%</entry></row></tbody></tgroup>
</table>
</tables>
<tables id="tabl0003" num="0003">
<table frame="all">
<title>&lt;Table 3&gt;</title>
<tgroup cols="3">
<colspec colnum="1" colname="col1" colwidth="12mm"/>
<colspec colnum="2" colname="col2" colwidth="53mm"/>
<colspec colnum="3" colname="col3" colwidth="14mm"/>
<thead>
<row>
<entry align="center" valign="middle">Test</entry>
<entry align="center" valign="middle">Reaction / Enzyme</entry>
<entry align="center" valign="middle">Result</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="middle">NO<sub>3</sub></entry>
<entry align="center" valign="middle">Reduction of nitrates to nitrites</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">Reduction of nitrates to nitrogen</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">TRP</entry>
<entry align="center" valign="middle">Indole production</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">GLU</entry>
<entry align="center" valign="middle">Acidification</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">ADH</entry>
<entry align="center" valign="middle">Arginine dihydrolase</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">URE</entry>
<entry align="center" valign="middle">Urease</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">ESC</entry>
<entry align="center" valign="middle">Hydrolysis (β-glucosidase)</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">GEL</entry>
<entry align="center" valign="middle">Hydrolysis(protease)</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">PNG</entry>
<entry align="center" valign="middle">β-glucosidase</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">GLU</entry>
<entry align="center" valign="middle">Glucose assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">RAR</entry>
<entry align="center" valign="middle">Arabinose assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">MNE</entry>
<entry align="center" valign="middle">Mannose assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">MAN</entry>
<entry align="center" valign="middle">Mannitol assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">NAG</entry>
<entry align="center" valign="middle">N-acetyl-glucosamine assimilation</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">MAL</entry>
<entry align="center" valign="middle">Maltose assimilation</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">GNT</entry>
<entry align="center" valign="middle">Gluconate assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">CAP</entry>
<entry align="center" valign="middle">Caprate assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">ADI</entry>
<entry align="center" valign="middle">Adipate assimilation</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">MLT</entry>
<entry align="center" valign="middle">Malate assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">CIT</entry>
<entry align="center" valign="middle">Citrate assimilation</entry>
<entry align="center" valign="middle">+</entry></row>
<row>
<entry align="center" valign="middle">PAC</entry>
<entry align="center" valign="middle">Phenyl-acetate assimilation</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle">OX</entry>
<entry align="center" valign="middle">Cytochrome oxidase</entry>
<entry align="center" valign="middle">+</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0043" num="0043">Also, the inventive strain was identified based on 16S rDNA nucleotide<!-- EPO <DP n="11"> --> sequencing. The isolated strain has 16s rDNA of 1,479 bp nucleotide sequence (SEQ ID NO: 1) which shows 99.05% sequence homology to that of <i>Pseudomonas oleovorans</i> IAM 1508T strain. The taxonomic position of the inventive strain was determined by constructing a phylogenetic tree (<figref idref="f0001">Fig. 1</figref>) according to Clustal method (<nplcit id="ncit0003" npl-type="s"><text>Thompson JD et al., Nuc. Acid. Res. 25: 4876-82, 1997</text></nplcit>).</p>
<p id="p0044" num="0044">The strain was designated as <i>Pseudomonas oleovorans</i> KBPF-004, and deposited on January 11, 2002 at Korean Collection for Type Cultures (KCTC) under the accession number of KCTC 10159BP.</p>
<heading id="h0009"><u>&lt;1-3&gt; Specificity of KBPF-004 strain having anti-viral activities</u></heading>
<p id="p0045" num="0045">KBPF-004 strain and <i>Pseudomonas oleovorans</i> ATCC 8062 as a type strain thereof were cultured in the Mueller Hinton medium with shaking at 30 °C for 24 hours. The obtained culture was diluted 20-fold and the anti-viral activities thereof were examined according to a tobacco half-leaf method (<nplcit id="ncit0004" npl-type="s"><text>Kim et al., Plant Pathol. J. 20(4): 293-296, 2004</text></nplcit>).</p>
<p id="p0046" num="0046">The tobacco half-leaf method is a method employing a phenomenon that <i>Nicotiana tabacum</i> cv. Xanthi nc as a local lesion host plant forms black spots due to the cell necrosis around the Tobacco mosaic virus-infected regions by the resistance gene of the Tobacco mosaic virus. Specifically, a test material for examining anti-viral activity was sprayed onto half-leaves of the upper 3<sup>rd</sup> and 4<sup>th</sup> leaves of the local lesion host plant at 7 foliage leaf stages. Then, carborundum (abrasive) was evenly applied to the 3<sup>rd</sup> and 4<sup>th</sup> leaves and a dilution of the tobacco mosaic virus was applied thereto for the examination of the anti-viral activity of the test material. The applied carborundum induces scratches on the tobacco leaves and the tobacco mosaic virus pass into the host plants through the scratches. After 3-4 days from the inoculation, black spots were found in the infected leaves.</p>
<p id="p0047" num="0047">Control values of the test materials were calculated by the following formula and the results are shown in Table 4.<!-- EPO <DP n="12"> --> <maths id="math0001" num=""><math display="block"><mi mathvariant="normal">C</mi><mo>⁢</mo><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">n</mi><mo>⁢</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">r</mi><mo>⁢</mo><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">l</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">v</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">u</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mspace width="1em"/><mfenced><mo mathvariant="normal">%</mo></mfenced><mo mathvariant="normal">=</mo><mfenced open="[" close="]" separators=""><mn mathvariant="normal">1</mn><mo mathvariant="normal">-</mo><mfenced separators=""><mi mathvariant="normal">N</mi><mo>⁢</mo><mi mathvariant="normal">u</mi><mo>⁢</mo><mi mathvariant="normal">m</mi><mo>⁢</mo><mi mathvariant="normal">b</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">r</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">f</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">b</mi><mo>⁢</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">c</mi><mo>⁢</mo><mi mathvariant="normal">k</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">s</mi><mo>⁢</mo><mi mathvariant="normal">p</mi><mo>⁢</mo><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">s</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">i</mi><mo>⁢</mo><mi mathvariant="normal">n</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">h</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">s</mi><mo>⁢</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">r</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">i</mi><mo>⁢</mo><mi mathvariant="normal">n</mi><mo mathvariant="normal">-</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">r</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">d</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">h</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">f</mi><mo mathvariant="normal">-</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">v</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">s</mi><mo mathvariant="normal">/</mo><mi mathvariant="normal">N</mi><mo>⁢</mo><mi mathvariant="normal">u</mi><mo>⁢</mo><mi mathvariant="normal">m</mi><mo>⁢</mo><mi mathvariant="normal">b</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">r</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">f</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">b</mi><mo>⁢</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">c</mi><mo>⁢</mo><mi mathvariant="normal">k</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">s</mi><mo>⁢</mo><mi mathvariant="normal">p</mi><mo>⁢</mo><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">s</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">i</mi><mo>⁢</mo><mi mathvariant="normal">n</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">h</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo mathvariant="normal">⁢</mo><mspace width="1em"/><mi mathvariant="normal">n</mi><mo>⁢</mo><mi mathvariant="normal">o</mi><mo>⁢</mo><mi mathvariant="normal">n</mi><mo mathvariant="normal">-</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">r</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">t</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">d</mi><mspace width="1em"/><mo mathvariant="normal">⁢</mo><mi mathvariant="normal">h</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">f</mi><mo mathvariant="normal">-</mo><mi mathvariant="normal">l</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">a</mi><mo>⁢</mo><mi mathvariant="normal">v</mi><mo>⁢</mo><mi mathvariant="normal">e</mi><mo>⁢</mo><mi mathvariant="normal">s</mi></mfenced><mspace width="1em"/><mi mathvariant="normal">X</mi><mspace width="1em"/><mn mathvariant="normal">100</mn></mfenced></math><img id="ib0001" file="imgb0001.tif" wi="162" he="24" img-content="math" img-format="tif"/></maths>
<tables id="tabl0004" num="0004">
<table frame="all">
<title>&lt;Table 4&gt;</title>
<tgroup cols="3">
<colspec colnum="1" colname="col1" colwidth="29mm"/>
<colspec colnum="2" colname="col2" colwidth="65mm"/>
<colspec colnum="3" colname="col3" colwidth="27mm"/>
<thead>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">Strain</entry>
<entry align="center" valign="middle">Anti-viral activity</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Type strain</entry>
<entry align="center" valign="middle"><i>Pseudomonas oleovorans</i> ATCC 8062</entry>
<entry align="center" valign="middle">19.7%</entry></row>
<row>
<entry align="center" valign="middle">KBPF-004 strain</entry>
<entry align="center" valign="middle"><i>Pseudomonas oleovorans</i> KCTC 10159BP</entry>
<entry align="center" valign="middle">96.0%</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0048" num="0048">As shown in Table 4, KBPF-004 strain has a specifically high anti-viral activity, which demonstrates that KBPF-004 strain is a specific strain having a different anti-viral activity compared with the existing <i>Pseudomonas oleovorans</i> strains.</p>
<heading id="h0010"><u>&lt;1-4&gt; Specificity of anti-viral active materials of KBPF-004</u></heading>
<p id="p0049" num="0049">It is known that <i>Pseudomonas oleovorans</i> species produce polyhydroxy alkanoate (PHA) as a biodegradable polymer. In order to identify whether the specific anti-viral activity of KBPF-004 strain is induced by PHA or not, the anti-viral activity of PHA (sigma) and a culture of KBPF-004 strain was respectively determined according to the tobacco half-leaf method, and the results are shown in Table 5.
<tables id="tabl0005" num="0005">
<table frame="all">
<title>&lt;Table 5&gt;</title>
<tgroup cols="2">
<colspec colnum="1" colname="col1" colwidth="38mm"/>
<colspec colnum="2" colname="col2" colwidth="27mm"/>
<thead>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">Anti-viral activity</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">PHA</entry>
<entry align="center" valign="middle">0.0%</entry></row>
<row>
<entry align="center" valign="middle">KBPF-004 strain culture</entry>
<entry align="center" valign="middle">97.0%</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0050" num="0050">As shown in Table 5, PHA exhibits no anti-viral activity, whereas KBPF-004 strain culture exhibits a high anti-viral activity. These results prove that the anti-viral active materials produced by KBPF-004 strain are different from PHA.<!-- EPO <DP n="13"> --></p>
<p id="p0051" num="0051">Further, in order to identify whether the anti-viral active materials produced by KBPF-004 strain also exhibits an antibiotic effect or not, the paper disk analysis was conducted using seven plant pathogenic fungi and four antibiotic supersensitive strains to check the formulation of inhibition circles. The results are shown in Table 6.
<tables id="tabl0006" num="0006">
<table frame="all">
<title>&lt;Table 6&gt;</title>
<tgroup cols="3">
<colspec colnum="1" colname="col1" colwidth="39mm"/>
<colspec colnum="2" colname="col2" colwidth="49mm"/>
<colspec colnum="3" colname="col3" colwidth="15mm"/>
<thead>
<row>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">Scientific name</entry>
<entry align="center" valign="middle">Activity</entry></row></thead>
<tbody>
<row>
<entry morerows="6" align="center" valign="middle">Plant pathogenic<br/>
fungi</entry>
<entry align="center" valign="middle"><i>Alternaria mali</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>Botrytis cinerea</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>Colletotrichum gloeosporioides</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>Magnaporthe grisea</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>Fusarium oxysporum</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>Phytophthora capsici</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>Rhizoctonia solani</i></entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry morerows="3" align="center" valign="middle">Antibiotic<br/>
supersensitive strain</entry>
<entry align="center" valign="middle"><i>E.coli</i> KCTC 1682</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>E.coli</i> KCTC 1683</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>E.coli</i> KCTC 1923</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry align="center" valign="middle"><i>E. coli</i> KCTC 1924</entry>
<entry align="center" valign="middle">-</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0052" num="0052">As shown in Table 6, both the plant pathogenic fungi and antibiotic supersensitive strains grow without inhibition by the KBPF-004 strain culture. It demonstrates that the anti-viral active materials produced by KBPF-004 strain are different from the existing antibiotic materials.</p>
<heading id="h0011"><b>Example 2: Preparation of optimized medium for producing anti-viral active materials</b></heading>
<p id="p0053" num="0053">In order to determine a medium condition for producing anti-viral active 13<!-- EPO <DP n="14"> --> materials superior to the Mueller Hinton medium, a variety of carbon and nitrogen sources were employed for preparing an optimized medium.</p>
<p id="p0054" num="0054">Specifically, the strain was subjected to shaking culture at 30 °C for 24 hours by using dextrin, glucose, glycerol, sucrose or water-soluble starch as a carbon source, and peptone, yeast extract, casein, wheat bran extract, ammonium dihydrogen phosphate or ammonium sulfate as a nitrogen source. The optical density (O.D) of the obtained culture was measured at 600 nm, and the anti-viral activity was determined by the tobacco half-leaf method. The results are shown in Table 7.
<tables id="tabl0007" num="0007">
<table frame="all">
<title>&lt;Table 7&gt;</title>
<tgroup cols="3">
<colspec colnum="1" colname="col1" colwidth="37mm"/>
<colspec colnum="2" colname="col2" colwidth="47mm"/>
<colspec colnum="3" colname="col3" colwidth="38mm"/>
<thead>
<row>
<entry align="center" valign="middle">Medium</entry>
<entry align="center" valign="middle">Anti-viral activity (1/40 dilution)</entry>
<entry align="center" valign="middle">Optical density (660 nm)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Mueller Hinton medium</entry>
<entry align="center" valign="middle">57%</entry>
<entry align="center" valign="middle">9.2</entry></row>
<row>
<entry align="center" valign="middle">Optimized medium</entry>
<entry align="center" valign="middle">92%</entry>
<entry align="center" valign="middle">23.2</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0055" num="0055">As shown in Table 7, the optimized medium supplemented with 1 to 5% by weight of glucose as a carbon source and 1 to 5% by weight of yeast extract as a nitrogen source presents a significantly improved strain growth and anti-viral activity compared with the Mueller Hinton medium.</p>
<heading id="h0012"><b>Example 3: Preparation of a culture and a dried powder of KBPF-004 strain</b></heading>
<heading id="h0013"><u>&lt;3-1&gt; Preparation of a culture of KBPF-004 strain</u></heading>
<p id="p0056" num="0056">In order to prepare a culture of KBPF-004 strain on a large scale, a medium supplemented with 10 g of glucose, 20 g of yeast extract, 0.2 g of magnesium sulfate, 2 g of potassium dihydrogen phosphate and 2 g of potassium hydrogen phosphate based on 1 ℓ of water was employed.</p>
<p id="p0057" num="0057">A fermentation process for production on a large scale was conducted by employing a pilot-scale fermentor. 30 ℓ of strain culture was fermented in a 50 ℓ fermentor and the resulting culture was transported to a 500 ℓ fermentor upon<!-- EPO <DP n="15"> --> terminating the culturing. Along the same lines, 3,000 ℓ of strain culture was fermented in a 5,000 ℓ fermentor. The fermentation process was conducted at a temperature of 30°C, with an aeration rate of 1VVM (volume of air added to liquid volume per minute), and a rotation speed of 200 rpm (50 ℓ fermentor), 150 rpm (500 ℓ fermentor) or 80 rpm (5,000 ℓ fermentor) for 1 day to prepare the KBPF-004 strain culture.</p>
<heading id="h0014"><u>&lt;3-2&gt; Preparation of a dried powder of KBPF-004 strain culture</u></heading>
<p id="p0058" num="0058">In order to prepare a dried powder of the KBPF-004 strain culture, post-treatment process comprising strain sterilization, concentration, freeze-drying and milling was conducted.</p>
<p id="p0059" num="0059">The strain sterilization process was conducted by heating the fermentor at 80 °C for 20 min after the culturing to kill the cells. The concentration process was conducted by concentrating the resulting culture under a reduced pressure at 65°C for 32 hours. The freeze-drying process was conducted by heating the concentrated culture with gradually raising the temperature starting from -80 °C for 52 hours. The milling process was conducted by grinding the freeze-dried products using a pin mill grinder to prepare a dried powder having a particle size of below 2 mm.</p>
<heading id="h0015"><b>Example 4: Preparation of microbial agents using products of KBPF-004 strain culture</b></heading>
<p id="p0060" num="0060">Microbial agents of KBPF-004 strain such as wettable powders (WP), water dispersible granules (WG), suspension concentrates (SC) and granules were prepared by using the dried powder of the KBPF-004 strain culture, and aqueous suspensions (AS) were prepared by using the aqueous KBPF-004 strain culture.</p>
<heading id="h0016"><u>&lt;4-1&gt; Preparation of a wettable powder using dried powder of the KBPF-004 strain culture</u></heading><!-- EPO <DP n="16"> -->
<p id="p0061" num="0061">In order to formulate a wettable powder from the dried powder of the KBPF-004 strain culture, 25% by weight of the dried powder of the KBPF-004 strain culture obtained in &lt;3-2&gt; was mixed with 3% by weight of polyoxyethylene octylphenylsulfate, 3% by weight of sodium lignin sulfonate, 2% by weight of sodium laurylsulfate, 5% by weight of white carbon and a residual amount of kaolin, and the mixture was ground using a drying type grinding machine. The average particle size of the ground mixture was 6.47 µm. The wettable powder thus obtained was subjected to physicochemical and biological analyses, and the results are shown in &lt;4-6&gt; below.</p>
<heading id="h0017"><u>&lt;4-2&gt; Preparation of water dispersible granule using dried powder of the KBPF-004 strain culture</u></heading>
<p id="p0062" num="0062">In order to formulate water dispersible granules from the dried powder the KBPF-004 strain culture, 25% by weight of the dried powder of the KBPF-004 strain culture obtained in &lt;3-2&gt; was mixed with 6% by weight of sodium naphthalene sulfonate formalin condensate, 2% by weight of sodium laurylsulfate, 2% by weight of sodium lignin sulfonate, 5% by weight of diatomaceous earth and a residual amount of calcium carbonate, and the mixture was ground using a drying type grinding machine. The average particle size of the ground mixture was 6.08 µm. Then, 10% by weight of water based on the mixture was added to the mixture, and the resulting mixture was subjected to kneading and molding process using a granulating machine and dried for 30 min in a fluidized bed dryer to obtain the water dispersible granules. The water dispersible granules thus obtained were subjected to physicochemical and biological analyses, and the results are shown in &lt;4-6&gt; below.</p>
<heading id="h0018"><u>&lt;4-3&gt; Preparation of a suspension concentrate using dried powder of the KBPF-004 strain culture</u></heading>
<p id="p0063" num="0063">In order to formulate a suspension concentrate from the dried powder the KBPF-004 strain culture, 25% by weight of the dried powder of the KBPF-004<!-- EPO <DP n="17"> --> strain culture obtained in &lt;3-2&gt; was mixed with 3% by weight of polyoxyethylene octylphenyl ether, 2% by weight of ethyleneoxide propyleneoxide copolymer, 2% by weight of sodium dioctylsulfosuccinate, 10% by weight of propylene glycol and 55.5% by weight of distilled water, and the resulting mixture was ground using a wet grinding machine. The average particle size of the ground mixture was 2.45 µm. Then, 2.5 % by weight of 2% aqueous xanthan gum prepared by stirring and mixing steps was added to the mixture, and the resulting mixture was stirred and mixed by a mixer to obtain a suspension concentrate in the form of an aqueous suspension. The suspension concentrate thus obtained was subjected to physicochemical and biological analyses, and the results are shown in &lt;4-6&gt; below.</p>
<heading id="h0019"><u>&lt;4-4&gt; Preparation of granules using dried powder of the KBPF-004 strain culture</u></heading>
<p id="p0064" num="0064">In order to examine the controlling effect of the KBPF-004 strain when applied to the soils, 2.5% by weight of the dried powder of the KBPF-004 strain culture obtained in &lt;3-2&gt; was mixed with 0.5% by weight of calcium lignin sulfonate and 1.5% by weight of kaolin, and the mixture was ground using a drying type grinding machine to prepare a ground mixture having an average particle size of 6.25 µm. 1% by weight of polyvinyl alcohol and 0.5% by weight of dextrin were dissolved in 1.5% by weight of water to prepare a binding solution. The binding solution was applied to 94% by weight of sand, and the above-prepared mixture was coated thereon. The resulting granules were dried in a fluidized bed dryer for 30 min. The granules thus obtained were subjected to physicochemical and biological analyses, and the results are shown in &lt;4-6&gt; below.</p>
<heading id="h0020"><u>&lt;4-5&gt; Preparation of aqueous suspensions using the KBPF-004 strain culture</u></heading>
<p id="p0065" num="0065">In order to formulate aqueous suspensions from the aqueous KBPF-004 strain culture, the aqueous KBPF-004 strain culture obtained in &lt;3-1&gt; was subjected to the post-treatment process comprising the strain killing and<!-- EPO <DP n="18"> --> concentration, and 70% by weight of the strain culture thus obtained was mixed with 5% by weight of polyoxyethylene octylphenyl ether, 5% by weight of sodium dioctylsulfosuccinate, 10% by weight of propylene glycol and 10 % by weight of ethanol. The resulting mixture was stirred and mixed to obtain the aqueous suspensions. The aqueous suspensions thus obtained were subjected to physicochemical and biological analyses, and the results are shown in &lt;4-6&gt; below.</p>
<heading id="h0021"><u>&lt;4-6&gt; Test of the formulation properties and anti-viral effect against tobacco mosaic virus</u></heading>
<p id="p0066" num="0066">The properties (formulation form, appearance, wettability, fineness and storage stability) and the control values according to the tobacco half-leaf method of the formulations obtained in &lt;4-1&gt; to &lt;4-5&gt; were determined and the results are shown in Table 8 (Test method of agricultural chemicals notified by the Korean <i>Rural development administration</i>).
<tables id="tabl0008" num="0008">
<table frame="all">
<title>&lt;Table 8&gt;</title>
<tgroup cols="7">
<colspec colnum="1" colname="col1" colwidth="18mm"/>
<colspec colnum="2" colname="col2" colwidth="24mm"/>
<colspec colnum="3" colname="col3" colwidth="23mm"/>
<colspec colnum="4" colname="col4" colwidth="22mm"/>
<colspec colnum="5" colname="col5" colwidth="27mm"/>
<colspec colnum="6" colname="col6" colwidth="27mm"/>
<colspec colnum="7" colname="col7" colwidth="28mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Example</entry>
<entry namest="col2" nameend="col6" align="center" valign="middle">Properties</entry>
<entry morerows="1" align="center" valign="middle">Control<br/>
value<br/>
(%)</entry></row>
<row>
<entry align="center" valign="middle">Formulation</entry>
<entry align="center" valign="middle">Appearance</entry>
<entry align="center" valign="middle">Wettability</entry>
<entry align="center" valign="middle">Fineness</entry>
<entry align="center" valign="middle">Storage stability</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">&lt;4-1&gt;</entry>
<entry align="center" valign="middle">25% WP</entry>
<entry align="center" valign="middle">powder</entry>
<entry align="center" valign="middle">58 sec</entry>
<entry align="center" valign="middle">99.3%</entry>
<entry align="center" valign="middle">Good</entry>
<entry align="center" valign="middle">95.7</entry></row>
<row>
<entry align="center" valign="middle">&lt;4-2&gt;</entry>
<entry align="center" valign="middle">25% WG</entry>
<entry align="center" valign="middle">granule</entry>
<entry align="center" valign="middle">1 min 10 sec</entry>
<entry align="center" valign="middle">99.6%</entry>
<entry align="center" valign="middle">Good</entry>
<entry align="center" valign="middle">85.8</entry></row>
<row>
<entry align="center" valign="middle">&lt;4-3&gt;</entry>
<entry align="center" valign="middle">25% SC</entry>
<entry align="center" valign="middle">liquid</entry>
<entry align="center" valign="middle">20 sec</entry>
<entry align="center" valign="middle">99.7%</entry>
<entry align="center" valign="middle">Good</entry>
<entry align="center" valign="middle">90.4</entry></row>
<row>
<entry align="center" valign="middle">&lt;4-4&gt;</entry>
<entry align="center" valign="middle">2.5% granule</entry>
<entry align="center" valign="middle">granule</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">Good</entry>
<entry align="center" valign="middle">92.3</entry></row>
<row>
<entry align="center" valign="middle">&lt;4-5&gt;</entry>
<entry align="center" valign="middle">70% AS</entry>
<entry align="center" valign="middle">liquid</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">Good</entry>
<entry align="center" valign="middle">91.3</entry></row>
<row>
<entry namest="col1" nameend="col3" align="center" valign="middle">Standard of review</entry>
<entry align="center" valign="middle">About 2 min</entry>
<entry align="center" valign="middle">44 µm, at least 98%</entry>
<entry align="center" valign="middle">50°C 4 weeks</entry>
<entry align="center" valign="middle">Tobacco half-leaf method</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0067" num="0067">As a result, the five formulations showed suitable physical properties and anti-viral effect according to the standard of review of agricultural chemicals by enforcement regulations of the Korean agrochemical management law. Among<!-- EPO <DP n="19"> --> formulations, 25% wettable powder obtained in &lt;4-1&gt; showed the most excellent anti-viral effect, therefore, the KBPF-004 25% wettable powder, 2.5% granule and 70% AS were employed in the following tests.</p>
<heading id="h0022"><u>&lt;4-7&gt; Test for aging stability of 25% wettable powder</u></heading>
<p id="p0068" num="0068">In order to test the aging stability of the 25% wettable powder obtained in &lt;4-1&gt;, the degree of loss of the anti-viral activity of the wettable powder was determined by the tobacco half-leaf method every one week while storing at 54°C for at least 6 weeks, and the results are shown in <figref idref="f0002">Fig. 2</figref>. As shown in <figref idref="f0002">Fig. 2</figref>, the inventive wettable powder exhibited the anti-viral activity on the tobacco mosaic virus at 54°C for at least 6 weeks. Therefore, a three year warranty of efficacy was set for the inventive wettable powder according to the registration test guidelines and methods of agricultural chemicals notified by the Korean Rural development administration.</p>
<heading id="h0023"><b>Example 5: Test for inhibiting effect of KBPF-004 25% wettable powder on plant viruses</b></heading>
<heading id="h0024"><u>&lt;5-1&gt; Concentration-dependent inhibiting effect on tobacco mosaic virus infection</u></heading>
<p id="p0069" num="0069">In order to examine the inhibiting effect of the KBPF-004 25% wettable powder on Tobacco mosaic virus-infection according to its concentrations, RT-PCR (Reverse transcriptase-polymerase chain reaction) was performed on the tobacco leaves using primers recognizing a specific nucleotide sequence of virus genomic RNA (protein coat region) (<nplcit id="ncit0005" npl-type="s"><text>Choi et al., Plant Pathol, J. , 14: 7-12, 1998</text></nplcit>; <nplcit id="ncit0006" npl-type="b"><text>Yoon, Doctoral Thesis, Seoul Women's Univ., Seoul, 166, 2003</text></nplcit>) and the results are shown in <figref idref="f0002">Fig. 3</figref>.</p>
<p id="p0070" num="0070">As shown in <figref idref="f0002">Fig. 3</figref>, no Tobacco mosaic virus was detected when the tobacco leaves were treated with KBPF-004 25% wettable powder in an amount ranging from 0.005 g/ml to 0.02 g/ml. This result shows that KBPF-004 strain<!-- EPO <DP n="20"> --> effectively inhibits the Tobacco mosaic virus infection.</p>
<heading id="h0025"><u>&lt;5-2&gt; Controlling effect on plant viral infection</u></heading>
<p id="p0071" num="0071">In order to examine the controlling effect of the KBPF-004 25% wettable powder on single and complex infection of the plant viruses, 1,000-fold dilution of the KBPF-004 25% wettable powder obtained in &lt;4-1&gt; was sprayed on Chungyang red peppers using a sprayer. Then, Pepper mottle virus (PepMoV), Pepper mild mottle virus (PMMoV) and Cucumber mosaic virus (CMV) were inoculated thereto respectively or in combination, and RT-PCR was conducted to identify whether the RT-PCR products were detected or not. The results are shown in <figref idref="f0003">Fig. 4</figref>.</p>
<p id="p0072" num="0072">As shown in <figref idref="f0003">Fig. 4</figref>, the Chungyang red peppers inoculated with PepMoV only showed no virus up to 30-40 days regardless of their species, and the Chungyang red peppers inoculated with Pepper mottle virus + Cucumber mosaic virus showed no virus up to 30 days.</p>
<p id="p0073" num="0073">Also, the Pepper mottle virus, Pepper mottle virus + Pepper mild mottle virus, and Pepper mottle virus + Cucumber mosaic virus samples to which the anti-viral activities were confirmed in RT-PCR analysis were analyzed using ELISA (enzyme-linked immunosorbent assay)(<nplcit id="ncit0007" npl-type="s"><text>Clark, et al., J. Gen. virol. 34: 475-483, 1977</text></nplcit>) and the results are shown in Table 9.<!-- EPO <DP n="21"> -->
<tables id="tabl0009" num="0009">
<table frame="all">
<title>&lt;Table 9&gt;</title>
<tgroup cols="6">
<colspec colnum="1" colname="col1" colwidth="32mm"/>
<colspec colnum="2" colname="col2" colwidth="20mm"/>
<colspec colnum="3" colname="col3" colwidth="31mm"/>
<colspec colnum="4" colname="col4" colwidth="31mm"/>
<colspec colnum="5" colname="col5" colwidth="31mm"/>
<colspec colnum="6" colname="col6" colwidth="23mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Infected virus</entry>
<entry morerows="1" align="center" valign="middle">Antiserum</entry>
<entry morerows="1" align="center" valign="middle">The days after inoculation</entry>
<entry namest="col4" nameend="col6" align="center" valign="middle">Absorbance (A<sub>405nm</sub>)</entry></row>
<row>
<entry align="center" valign="middle">KBPF-004 treated group</entry>
<entry align="center" valign="middle">Non-treated group</entry>
<entry align="center" valign="middle">Healthy plant</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="middle">PepMoV<br/>
(single infected)</entry>
<entry morerows="1" align="center" valign="middle">PepMoV</entry>
<entry align="center" valign="middle">10</entry>
<entry align="center" valign="middle">0.202</entry>
<entry align="center" valign="middle">0.981</entry>
<entry align="center" valign="middle">0.232</entry></row>
<row>
<entry align="center" valign="middle">30</entry>
<entry align="center" valign="middle">0.210</entry>
<entry align="center" valign="middle">1.900</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry morerows="3" align="center" valign="middle">PepMoV + PMMoV<br/>
(complex infected)</entry>
<entry morerows="1" align="center" valign="middle">PepMoV</entry>
<entry align="center" valign="middle">10</entry>
<entry align="center" valign="middle">0.173</entry>
<entry align="center" valign="middle">1.200</entry>
<entry align="center" valign="middle">0.243</entry></row>
<row>
<entry align="center" valign="middle">30</entry>
<entry align="center" valign="middle">0.788</entry>
<entry align="center" valign="middle">1.876</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry morerows="1" align="center" valign="middle">PMMoV</entry>
<entry align="center" valign="middle">10</entry>
<entry align="center" valign="middle">0.836</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">0.243</entry></row>
<row>
<entry align="center" valign="middle">30</entry>
<entry align="center" valign="middle">1.504</entry>
<entry align="center" valign="middle">1.366</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry morerows="3" align="center" valign="middle">PepMoV + CMV<br/>
(complex infected)</entry>
<entry morerows="1" align="center" valign="middle">PepMoV</entry>
<entry align="center" valign="middle">10</entry>
<entry align="center" valign="middle">0.310</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">0.187</entry></row>
<row>
<entry align="center" valign="middle">30</entry>
<entry align="center" valign="middle">0.286</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">-</entry></row>
<row>
<entry morerows="1" align="center" valign="middle">CMV</entry>
<entry align="center" valign="middle">10</entry>
<entry align="center" valign="middle">0.457</entry>
<entry align="center" valign="middle">1.964</entry>
<entry align="center" valign="middle">0.187</entry></row>
<row>
<entry align="center" valign="middle">30</entry>
<entry align="center" valign="middle">0.382</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">-</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0074" num="0074">As shown in Table 9, the controlling effects of the inventive KBPF-004 strain were significantly shown in the molecular and antiserum levels.</p>
<heading id="h0026"><u>&lt;5-3&gt; Infection inhibiting effect on virus genome RNA</u></heading>
<p id="p0075" num="0075">In order to examine the inhibiting effect of the KBPF-004 25% wettable powder on the infection by Pepper mild mottle virus (PMMoV) genomic RNA, 1,000-fold dilution of the KBPF-004 25% wettable powder obtained in &lt;4-1&gt; was sprayed on tobacco (<i>Nicotiana glutinosa</i>) plants. Then, the genome RNA of the pepper mild mottle virus was inoculated to the plants, and the infection inhibiting effects were determined and the results are shown in Table 10.<!-- EPO <DP n="22"> -->
<tables id="tabl0010" num="0010">
<table frame="all">
<title>&lt;Table 10&gt;</title>
<tgroup cols="4">
<colspec colnum="1" colname="col1" colwidth="31mm"/>
<colspec colnum="2" colname="col2" colwidth="50mm"/>
<colspec colnum="3" colname="col3" colwidth="36mm"/>
<colspec colnum="4" colname="col4" colwidth="23mm"/>
<thead>
<row>
<entry namest="col1" nameend="col2" align="center" valign="middle">Treatment</entry>
<entry align="center" valign="middle">lesions / 3 half-leaves *</entry>
<entry align="center" valign="middle">Inhibition (%)</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Non-treated group</entry>
<entry align="center" valign="middle">PMMoV-RNA+phosphate buffer</entry>
<entry align="center" valign="middle">531</entry>
<entry align="center" valign="middle">0</entry></row>
<row>
<entry align="center" valign="middle">KBPF-004</entry>
<entry align="center" valign="middle">PMMoV-RNA+ phosphate buffer</entry>
<entry align="center" valign="middle">3</entry>
<entry align="center" valign="middle">99.4</entry></row>
<row rowsep="0">
<entry namest="col1" nameend="col4" align="center" valign="middle">* the number of lesions formed in</entry></row>
<row>
<entry namest="col1" nameend="col4" align="center" valign="middle">3 half-leaves of tobacco (<i>Nicotiana glutinosa</i>)</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0076" num="0076">As shown in Table 10, the KBPF-004 25% wettable powder-treated group shows no virus infection, whereas the non-treated group shows PMMoV infection, which suggests the KBPF-004 strain directly influences on the virus genome RNA.</p>
<heading id="h0027"><u>&lt;5-4&gt; Resistance inducing effect</u></heading>
<p id="p0077" num="0077">In order to examine the resistance inducing effect of the KBPF-004 25% wettable powder, 1,000-fold dilution of the KBPF-004 25% wettable powder was sprayed on the lower leaves of two tobacco species (<i>Nicotiana tabacum</i> cv. Xanthi nc and <i>Nicotiana glutinosa</i>). After 10 days, the Pepper mild mottle virus was inoculated thereto. The control values were calculated and the results are shown in Table 11.
<tables id="tabl0011" num="0011">
<table frame="all">
<title>&lt;Table 11&gt;</title>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="30mm"/>
<colspec colnum="2" colname="col2" colwidth="49mm"/>
<colspec colnum="3" colname="col3" colwidth="24mm"/>
<colspec colnum="4" colname="col4" colwidth="26mm"/>
<colspec colnum="5" colname="col5" colwidth="26mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Treatment</entry>
<entry morerows="1" align="center" valign="middle">Host plant</entry>
<entry namest="col3" nameend="col5" align="center" valign="middle">Number of lesions (Control value)</entry></row>
<row>
<entry align="center" valign="middle">Treated leave<br/>
(lower leave)</entry>
<entry align="center" valign="middle">1<sup>st</sup> upper leave</entry>
<entry align="center" valign="middle">2<sup>nd</sup> upper leave</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="middle">KBPF-004</entry>
<entry align="center" valign="middle"><i>Nicotiana tabacum</i> cv. Xanthi nc</entry>
<entry align="center" valign="middle">51 (71.0%)</entry>
<entry align="center" valign="middle">96 (55.9%)</entry>
<entry align="center" valign="middle">78 (57.3%)</entry></row>
<row>
<entry align="center" valign="middle"><i>Nicotiana glutinosa</i></entry>
<entry align="center" valign="middle">83 (74.8%)</entry>
<entry align="center" valign="middle">118 (45.8%)</entry>
<entry align="center" valign="middle">169 (46.6%)</entry></row>
<row>
<entry morerows="1" align="center" valign="middle">Non-treated group</entry>
<entry align="center" valign="middle"><i>Nicotiana tabacum</i> cv. Xanthi nc</entry>
<entry align="center" valign="middle">176</entry>
<entry align="center" valign="middle">218</entry>
<entry align="center" valign="middle">183</entry></row>
<row>
<entry align="center" valign="middle"><i>Nicotiana glutinosa</i></entry>
<entry align="center" valign="middle">330</entry>
<entry align="center" valign="middle">349</entry>
<entry align="center" valign="middle">317</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="23"> --></p>
<p id="p0078" num="0078">As shown in Table 11, in the KBPF-004 25% wettable powder-treated group, the controlling effect on Pepper mild mottle virus was shown in the 1<sup>st</sup> and 2<sup>nd</sup> upper leaves as well as the treated leaves (lower leaves). Therefore, it is shown that the KBPF-004 25% wettable powder has a resistance inducing effect as well as the direct inhibiting effects on the virus infection and reproduction.</p>
<heading id="h0028"><u>&lt;5-5&gt; Virus inhibiting, effect confirmed by an electron microscopy.</u></heading>
<p id="p0079" num="0079">In order to confirm the direct virus inhibiting effect of the inventive microbial agent, effect of KBPF-004 strain on virus particles or viral coat protein was analyzed by an electron microscopy.</p>
<p id="p0080" num="0080">Tobacco mosaic virus (TMV) and Potato virus Y (PVY) were respectively inoculated on a host plant for proliferation (<i>Nicotiana benthamiana</i>). After 2 weeks, 50 g of the systemically infected leaves was collected and purified for the virus particles, respectively. Then, the purified virus particles were mixed with 1/100 dilution of the KBPF-004 25% wettable powder (1,000 ppm) in the ratio of 1:1 (v/v), and the resulting mixture was analyzed by an electron microscopy. The results are shown in <figref idref="f0004">Fig. 5</figref>.</p>
<p id="p0081" num="0081">As shown in <figref idref="f0004">Fig. 5</figref>, it is found that the length of the virus particles was short in the KBPF-004 25% wettable powder-treated group, which suggests that the particles of the TMV or PVY are segmented by the KBPF-004 strain.</p>
<p id="p0082" num="0082">Further, the segmented virus particle samples obtained in the above were subjected to the tobacco half-leaf method to examine whether the viral activity is maintained or not, and the results are shown in <figref idref="f0004">Fig. 6</figref>. As a result, the number of segmented virus particles was increased depending on the strain-treated time, and the number of infected lesions of the host plant was rapidly decreased.</p>
<heading id="h0029"><b>Example 6: Efficacy of KBPF-004 strain on the major plant viral diseases</b></heading>
<heading id="h0030"><u>&lt;6-1&gt; Efficacy screening</u></heading><!-- EPO <DP n="24"> -->
<p id="p0083" num="0083">In order to evaluate the efficacy of the microbial agent of KBPF-004 strain on the major plant viruses, an efficacy screening was conducted on a variety of plants in greenhouse pots.</p>
<p id="p0084" num="0084">The screening was conducted on seedlings (young plant), and adult plants, if necessary, according to a common method for screening plant viral diseases.</p>
<p id="p0085" num="0085">For the efficacy screening, Tobamovirus group such as Tobacco mosaic virus, Cucumber green mottle mosaic virus and Pepper mild mottle virus; Potyvirus group such as Pepper mottle virus, Zucchini yellow mosaic virus, Potato virus Y and Watermelon mosaic virus; Cucumovirus group such as Cucumber mosaic virus were employed as plant viruses, and tobacco, pepper, zucchini, cucumber, watermelon, pumpkin, cabbage and melon were employed as host plants.</p>
<p id="p0086" num="0086">Specifically, 250-, 500- and 1,000-fold dilutions of the KBPF-004 25% wettable powder obtained in &lt;4-1&gt; were sprayed on the host plants in an amount of 20L/1,000 m<sup>2</sup>, respectively, and 1,000-fold dilutions of the respective plant virus were inoculated thereto. The efficacy of the microbial agent was evaluated by the result of the tobacco half-leaf method for Tobacco mosaic virus, and by the control values calculated by using the diseased plant rate (%) according to the following formula for other viruses (⊚: Excellent; O: good; Δ; insufficient; and X: bad). The results are shown in Table 12. <maths id="math0002" num=""><math display="block"><mi>Diseased plant rate</mi><mspace width="1em"/><mfenced><mo>%</mo></mfenced><mo>=</mo><mfenced separators=""><mi>Number of diseased plant</mi><mo>/</mo><mi>Number of test plants</mi></mfenced><mspace width="1em"/><mi>X</mi><mspace width="1em"/><mn>100</mn></math><img id="ib0002" file="imgb0002.tif" wi="165" he="19" img-content="math" img-format="tif"/></maths> <maths id="math0003" num=""><math display="block"><mi>Control value</mi><mspace width="1em"/><mfenced><mo>%</mo></mfenced><mo>=</mo><mfenced open="[" close="]" separators=""><mn>1</mn><mo>-</mo><mrow><mo>(</mo><mi>Diseased plant rate of the treated plants</mi><mo>/</mo><mi>Diseased plant rate of the non</mi><mo>-</mo><mi>treated plants</mi></mrow></mfenced><mspace width="1em"/><mi>X</mi><mspace width="1em"/><mn>100</mn><mrow><mo>)</mo></mrow></math><img id="ib0003" file="imgb0003.tif" wi="165" he="30" img-content="math" img-format="tif"/></maths><!-- EPO <DP n="25"> -->
<tables id="tabl0012" num="0012">
<table frame="all">
<title>&lt;Table 12&gt;</title>
<tgroup cols="5">
<colspec colnum="1" colname="col1" colwidth="56mm"/>
<colspec colnum="2" colname="col2" colwidth="23mm"/>
<colspec colnum="3" colname="col3" colwidth="28mm"/>
<colspec colnum="4" colname="col4" colwidth="28mm"/>
<colspec colnum="5" colname="col5" colwidth="21mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Virus</entry>
<entry morerows="1" align="center" valign="middle">Host plant</entry>
<entry namest="col3" nameend="col5" align="center" valign="middle">Controlling activity</entry></row>
<row>
<entry align="center" valign="middle">250-fold dilution</entry>
<entry align="center" valign="middle">500-fold dilution</entry>
<entry align="center" valign="middle">1,000-fold<br/>
dilution</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">Tobacco mosaic virus</entry>
<entry align="center" valign="middle">Tobacco</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry></row>
<row>
<entry morerows="1" align="center" valign="middle">Cucumber green mottle mosaic virus</entry>
<entry align="center" valign="middle">Watermelon</entry>
<entry align="center" valign="middle">O</entry>
<entry align="center" valign="middle">O</entry>
<entry align="center" valign="middle">Δ</entry></row>
<row>
<entry align="center" valign="middle">Cucumber</entry>
<entry align="center" valign="middle">O</entry>
<entry align="center" valign="middle">O</entry>
<entry align="center" valign="middle">Δ</entry></row>
<row>
<entry align="center" valign="middle">Pepper mild mottle virus</entry>
<entry align="center" valign="middle">Pepper</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry></row>
<row>
<entry align="center" valign="middle">Pepper mottle virus</entry>
<entry align="center" valign="middle">Pepper</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry></row>
<row>
<entry align="center" valign="middle">Zucchini yellow mosaic virus</entry>
<entry align="center" valign="middle">Zucchini</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry></row>
<row>
<entry align="center" valign="middle">Watermelon mosaic virus</entry>
<entry align="center" valign="middle">Watermelon</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">○</entry>
<entry align="center" valign="middle">○</entry></row>
<row>
<entry morerows="1" align="center" valign="middle">Potato virus Y</entry>
<entry align="center" valign="middle">Cucumber</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry></row>
<row>
<entry align="center" valign="middle">Tobacco</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">⊚</entry></row>
<row>
<entry align="center" valign="middle">Cucumber mosaic virus</entry>
<entry align="center" valign="middle">Melon</entry>
<entry align="center" valign="middle">⊚</entry>
<entry align="center" valign="middle">○</entry>
<entry align="center" valign="middle">○</entry></row></tbody></tgroup>
</table>
</tables></p>
<heading id="h0031"><u>&lt;6-2&gt; Evaluation of efficacy in the field on Tobacco mosaic virus</u></heading>
<p id="p0087" num="0087">In the test of controlling efficacy on the Pepper mottle virus in &lt;6-1&gt;, the control value of the KBPF-004 25% wettable powder after 4 weeks from the inoculation of the Tobacco mosaic virus was calculated, and the results are shown in Table 13. As a result, the control value of 500-fold and 1,000-fold dilutions was 90.8% and 76.8%, respectively, which are higher than that of powdered skim milk as a control. Therefore, the anti-viral active materials of the KBPF-004 strain show a controlling effect in a concentration dependent manner.
<tables id="tabl0013" num="0013">
<table frame="all">
<title>&lt;Table 13&gt;</title>
<tgroup cols="9">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="22mm"/>
<colspec colnum="3" colname="col3" colwidth="12mm"/>
<colspec colnum="4" colname="col4" colwidth="12mm"/>
<colspec colnum="5" colname="col5" colwidth="12mm"/>
<colspec colnum="6" colname="col6" colwidth="17mm"/>
<colspec colnum="7" colname="col7" colwidth="23mm"/>
<colspec colnum="8" colname="col8" colwidth="23mm"/>
<colspec colnum="9" colname="col9" colwidth="25mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Group</entry>
<entry morerows="1" align="center" valign="middle">Dilution<br/>
ratio</entry>
<entry namest="col3" nameend="col6" align="center" valign="middle">Diseased plant rate (%)</entry>
<entry namest="col7" nameend="col8" morerows="1" align="center" valign="middle">Significant difference (DMRT)</entry>
<entry morerows="1" align="center" valign="middle">Control value (%)</entry></row>
<row>
<entry align="center" valign="middle">A</entry>
<entry align="center" valign="middle">B</entry>
<entry align="center" valign="middle">C</entry>
<entry align="center" valign="middle">Average</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="middle">KBPF-004<br/>
25% WP</entry>
<entry align="center" valign="middle">500-fold</entry>
<entry align="center" valign="middle">3.8</entry>
<entry align="center" valign="middle">1.9</entry>
<entry align="center" valign="middle">1.9</entry>
<entry align="center" valign="middle">2.5</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">90.8</entry></row>
<row>
<entry align="center" valign="middle">1,000-fold</entry>
<entry align="center" valign="middle">15.4</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">3.8</entry>
<entry align="center" valign="middle">6.4</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">76.8</entry></row>
<row>
<entry align="center" valign="middle">Powdered skim<br/>
milk</entry>
<entry align="center" valign="middle">10-fold</entry>
<entry align="center" valign="middle">23.5</entry>
<entry align="center" valign="middle">29.3</entry>
<entry align="center" valign="middle">15.4</entry>
<entry align="center" valign="middle">22.7</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle">17.5</entry></row>
<row>
<entry align="center" valign="middle">Non-treated group</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">32.7</entry>
<entry align="center" valign="middle">25.0</entry>
<entry align="center" valign="middle">25.0</entry>
<entry align="center" valign="middle">27.6</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle"/></row>
<row>
<entry namest="col1" nameend="col9" align="center" valign="middle">*Coefficient of variation (C.V.): 34.6%</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="26"> --></p>
<heading id="h0032"><u>&lt;6-3&gt; Evaluation of efficacy in the field on Pepper mottle virus</u></heading>
<p id="p0088" num="0088">In the test of controlling efficacy on the Pepper mottle virus in &lt;6-1&gt;, the control value of the KBPF-004 25% wettable powder was calculated and the results are shown in Table 14 and <figref idref="f0005">Fig. 7</figref>. The infection-inhibiting rates of 500-fold and 1,000-fold dilutions against pepper mottle virus were both 100%. In addition, in the non-treated group, the infection rate by the pepper mottle virus was 5.4% before treatment and increased to 11.8% after treatment. However, in the KBPF-004 25% wettable powder-treated group, the infection rate by the pepper mottle virus was decreased after treatment and the virus was not transmitted any more.
<tables id="tabl0014" num="0014">
<table frame="all">
<title>&lt;Table 14&gt;</title>
<tgroup cols="6">
<colspec colnum="1" colname="col1" colwidth="29mm"/>
<colspec colnum="2" colname="col2" colwidth="22mm"/>
<colspec colnum="3" colname="col3" colwidth="29mm"/>
<colspec colnum="4" colname="col4" colwidth="26mm"/>
<colspec colnum="5" colname="col5" colwidth="31mm"/>
<colspec colnum="6" colname="col6" colwidth="30mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Group</entry>
<entry morerows="1" align="center" valign="middle">Dilution<br/>
ratio</entry>
<entry namest="col3" nameend="col4" align="center" valign="middle">Virus infection rate (%)</entry>
<entry morerows="1" align="center" valign="middle">Infection progress (%)</entry>
<entry morerows="1" align="center" valign="middle">Infection inhibiting rate (%)</entry></row>
<row>
<entry align="center" valign="middle">Before treatment</entry>
<entry align="center" valign="middle">After treatment</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="middle">KBPF-004 25% WP</entry>
<entry align="center" valign="middle">1:500</entry>
<entry align="center" valign="middle">13.3</entry>
<entry align="center" valign="middle">9.5</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">100</entry></row>
<row>
<entry align="center" valign="middle">1: 1,000</entry>
<entry align="center" valign="middle">11.8</entry>
<entry align="center" valign="middle">11.8</entry>
<entry align="center" valign="middle">0</entry>
<entry align="center" valign="middle">100</entry></row>
<row>
<entry align="center" valign="middle">Non-treated group</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">5.4</entry>
<entry align="center" valign="middle">11.8</entry>
<entry align="center" valign="middle">203.4</entry>
<entry align="center" valign="middle">0</entry></row></tbody></tgroup>
</table>
</tables></p>
<heading id="h0033"><u>&lt;6-4&gt; Evaluation of efficacy of KBPF-004 strain on rice stripe virus in a greenhouse</u></heading>
<p id="p0089" num="0089">In the test of controlling efficacy on the rice stripe virus in &lt;6-1&gt;, 500-fold and 1,000-fold dilution of the KBPF-004 25% wettable powder was respectively sprayed on the rice seedlings 1 day before the inoculation of viruliferous insects (<i>Laodelphax striatllus F</i>). After 14 days from the inoculation of the viruliferous insects, the control value was calculated. As can be seen from the results shown in Table 15 and <figref idref="f0006">Fig. 8</figref>, 500-fold dilution exhibited excellent controlling efficacy compared with the non-treated group.<!-- EPO <DP n="27"> -->
<tables id="tabl0015" num="0015">
<table frame="all">
<title>&lt;Table 15&gt;</title>
<tgroup cols="9">
<colspec colnum="1" colname="col1" colwidth="25mm"/>
<colspec colnum="2" colname="col2" colwidth="23mm"/>
<colspec colnum="3" colname="col3" colwidth="10mm"/>
<colspec colnum="4" colname="col4" colwidth="10mm"/>
<colspec colnum="5" colname="col5" colwidth="10mm"/>
<colspec colnum="6" colname="col6" colwidth="17mm"/>
<colspec colnum="7" colname="col7" colwidth="23mm"/>
<colspec colnum="8" colname="col8" colwidth="23mm"/>
<colspec colnum="9" colname="col9" colwidth="26mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Group</entry>
<entry morerows="1" align="center" valign="middle">Dilution ratio</entry>
<entry namest="col3" nameend="col6" align="center" valign="middle">Disease severity (%)</entry>
<entry namest="col7" nameend="col8" morerows="1" align="center" valign="middle">Significant difference (DMRT)</entry>
<entry morerows="1" align="center" valign="middle">Control value (%)</entry></row>
<row>
<entry align="center" valign="middle">A</entry>
<entry align="center" valign="middle">B</entry>
<entry align="center" valign="middle">C</entry>
<entry align="center" valign="middle">Average</entry></row></thead>
<tbody>
<row>
<entry morerows="1" align="center" valign="middle">KBPF-004<br/>
25% WP</entry>
<entry align="center" valign="middle">500-fold</entry>
<entry align="center" valign="middle">4</entry>
<entry align="center" valign="middle">4</entry>
<entry align="center" valign="middle">2</entry>
<entry align="center" valign="middle">3.3</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">89.6</entry></row>
<row>
<entry align="center" valign="middle">1,000-fold</entry>
<entry align="center" valign="middle">16</entry>
<entry align="center" valign="middle">28</entry>
<entry align="center" valign="middle">10</entry>
<entry align="center" valign="middle">18.0</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle">43.8</entry></row>
<row>
<entry align="center" valign="middle">Non-treated group</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">44</entry>
<entry align="center" valign="middle">28</entry>
<entry align="center" valign="middle">24</entry>
<entry align="center" valign="middle">32.0</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle"/></row>
<row>
<entry namest="col1" nameend="col9" align="center" valign="middle">* Coefficient of variation (C.V.): 51.3 %</entry></row></tbody></tgroup>
</table>
</tables></p>
<p id="p0090" num="0090">In addition, 500-fold dilution of the KBPF-004 25% wettable powder was directly sprayed on the viruliferous insects (<i>Laodelphax striatllus F</i>) and after 1 day therefrom, the insects were inoculated to the rice seedlings. The control value was determined as above. As shown in Table 16, the transmission rate of the rice stripe virus was significantly decreased.
<tables id="tabl0016" num="0016">
<table frame="all">
<title>&lt;Table 16&gt;</title>
<tgroup cols="9">
<colspec colnum="1" colname="col1" colwidth="29mm"/>
<colspec colnum="2" colname="col2" colwidth="22mm"/>
<colspec colnum="3" colname="col3" colwidth="10mm"/>
<colspec colnum="4" colname="col4" colwidth="10mm"/>
<colspec colnum="5" colname="col5" colwidth="10mm"/>
<colspec colnum="6" colname="col6" colwidth="17mm"/>
<colspec colnum="7" colname="col7" colwidth="23mm"/>
<colspec colnum="8" colname="col8" colwidth="23mm"/>
<colspec colnum="9" colname="col9" colwidth="23mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Group</entry>
<entry morerows="1" align="center" valign="middle">Dilution<br/>
ratio</entry>
<entry namest="col3" nameend="col6" align="center" valign="middle">Disease severity (%)</entry>
<entry namest="col7" nameend="col8" morerows="1" align="center" valign="middle">Significant difference (DMRT)</entry>
<entry morerows="1" align="center" valign="middle">Control<br/>
value<br/>
(%)</entry></row>
<row>
<entry align="center" valign="middle">A</entry>
<entry align="center" valign="middle">B</entry>
<entry align="center" valign="middle">C</entry>
<entry align="center" valign="middle">Average</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">KBPF-004 25% WP</entry>
<entry align="center" valign="middle">500-fold</entry>
<entry align="center" valign="middle">0.5</entry>
<entry align="center" valign="middle">0.3</entry>
<entry align="center" valign="middle">0.1</entry>
<entry align="center" valign="middle">0.3</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">99.4</entry></row>
<row>
<entry align="center" valign="middle">Non-treated</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">54</entry>
<entry align="center" valign="middle">43</entry>
<entry align="center" valign="middle">65</entry>
<entry align="center" valign="middle">54.0</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle"/></row>
<row>
<entry namest="col1" nameend="col9" align="center" valign="middle">* Coefficient of variation (C.V.): 28.9 %</entry></row></tbody></tgroup>
</table>
</tables></p>
<heading id="h0034"><u>&lt;6-5&gt; Evaluation of efficacy of the KBPF-004 granules on Tobacco mosaic virus</u></heading>
<p id="p0091" num="0091">In order to examine the controlling efficacy of the KBPF-004 2.5% granules obtained in Example &lt;4-1&gt; when treated to the soils, a tobacco plant infected by Tobacco mosaic virus was freeze-dried and ground to prepare an infected source. 1 g of the infected source thus obtained was mixed with 100 g of bed soils to prepare diseased soils. Then, 1 g of the KBPF-004 2.5% granules was well mixed with 100 g of the diseased soils, and the local lesion host plant, tobacco (<i>Nicotiana tabacum</i> cv. Xanthi nc) of three foliage leaf stage was<!-- EPO <DP n="28"> --> transplanted thereto and cultivated in a greenhouse for 3 weeks.</p>
<p id="p0092" num="0092">As shown in Table 17 and <figref idref="f0006">Fig. 9</figref>, the tobacco seedlings withered in the non-treated group, but well grew like the healthy plants in the KBPF-004 2.5% granule-treated group.
<tables id="tabl0017" num="0017">
<table frame="all">
<title>&lt;Table 17&gt;</title>
<tgroup cols="9">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="24mm"/>
<colspec colnum="3" colname="col3" colwidth="12mm"/>
<colspec colnum="4" colname="col4" colwidth="12mm"/>
<colspec colnum="5" colname="col5" colwidth="12mm"/>
<colspec colnum="6" colname="col6" colwidth="17mm"/>
<colspec colnum="7" colname="col7" colwidth="23mm"/>
<colspec colnum="8" colname="col8" colwidth="23mm"/>
<colspec colnum="9" colname="col9" colwidth="24mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Group</entry>
<entry morerows="1" align="center" valign="middle">Treated amounts/soil</entry>
<entry namest="col3" nameend="col6" align="center" valign="middle">Diseased plant rate (%)</entry>
<entry namest="col7" nameend="col8" morerows="1" align="center" valign="middle">Significant difference (DMRT)</entry>
<entry morerows="1" align="center" valign="middle">Control value (%)</entry></row>
<row>
<entry align="center" valign="middle">A</entry>
<entry align="center" valign="middle">B</entry>
<entry align="center" valign="middle">C</entry>
<entry align="center" valign="middle">average</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">KBPF-004<br/>
25% granules</entry>
<entry align="center" valign="middle">1 g/100 g</entry>
<entry align="center" valign="middle">2.3</entry>
<entry align="center" valign="middle">3.2</entry>
<entry align="center" valign="middle">3.4</entry>
<entry align="center" valign="middle">3.0</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">93.3</entry></row>
<row>
<entry align="center" valign="middle">Non-treated</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">43.2</entry>
<entry align="center" valign="middle">39.3</entry>
<entry align="center" valign="middle">51.8</entry>
<entry align="center" valign="middle">44.8</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle"/></row>
<row>
<entry namest="col1" nameend="col9" align="center" valign="middle">* Coefficient of variation (C.V.): 18.4 %</entry></row></tbody></tgroup>
</table>
</tables></p>
<heading id="h0035"><u>&lt;6-6&gt; Evaluation of efficacy in the field on Tomato yellow leaf curl virus</u></heading>
<p id="p0093" num="0093">500-fold dilution of the KBPF-004 70% AS obtained in Example &lt;4-5&gt; was mixed with the conventional insecticides, such as Dinotefuran<sup>®</sup> WP, Dinotefuran<sup>®</sup> WG, Spiromesifen<sup>®</sup> SC, Dichlorvos<sup>®</sup> EC and Amitraz+buprofezin EC, and the mixture was sprayed to the tomato plants. The resulting control value was 99.9%. In contrast, when Spinosad WG, Acetamiprid WP, Dinotefuran WG, Spiromesifen SC, and Emamectin benzoate EC was alternatively sprayed to the plants at intervals of 7 days, the calculated diseased plant rate was 80.2%.
<tables id="tabl0018" num="0018">
<table frame="all">
<title>&lt;Table 18&gt;</title>
<tgroup cols="9">
<colspec colnum="1" colname="col1" colwidth="23mm"/>
<colspec colnum="2" colname="col2" colwidth="23mm"/>
<colspec colnum="3" colname="col3" colwidth="12mm"/>
<colspec colnum="4" colname="col4" colwidth="12mm"/>
<colspec colnum="5" colname="col5" colwidth="12mm"/>
<colspec colnum="6" colname="col6" colwidth="17mm"/>
<colspec colnum="7" colname="col7" colwidth="23mm"/>
<colspec colnum="8" colname="col8" colwidth="23mm"/>
<colspec colnum="9" colname="col9" colwidth="24mm"/>
<thead>
<row>
<entry morerows="1" align="center" valign="middle">Group</entry>
<entry morerows="1" align="center" valign="middle">Dilution ratio</entry>
<entry namest="col3" nameend="col6" align="center" valign="middle">Diseased plant rate (%)</entry>
<entry namest="col7" nameend="col8" morerows="1" align="center" valign="middle">Significant difference (DMRT)</entry>
<entry morerows="1" align="center" valign="middle">Control value (%)</entry></row>
<row>
<entry align="center" valign="middle">A</entry>
<entry align="center" valign="middle">B</entry>
<entry align="center" valign="middle">C</entry>
<entry align="center" valign="middle">Average</entry></row></thead>
<tbody>
<row>
<entry align="center" valign="middle">KBPF-004<br/>
70% AS</entry>
<entry align="center" valign="middle">500-fold</entry>
<entry align="center" valign="middle">0.2</entry>
<entry align="center" valign="middle">0.1</entry>
<entry align="center" valign="middle">0.1</entry>
<entry align="center" valign="middle">0.1</entry>
<entry align="center" valign="middle">a</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">99.9</entry></row>
<row>
<entry align="center" valign="middle">The conventional insecticides</entry>
<entry align="center" valign="middle">-</entry>
<entry align="center" valign="middle">77.6</entry>
<entry align="center" valign="middle">74.5</entry>
<entry align="center" valign="middle">88.4</entry>
<entry align="center" valign="middle">80.2</entry>
<entry align="center" valign="middle"/>
<entry align="center" valign="middle">b</entry>
<entry align="center" valign="middle"/></row>
<row>
<entry namest="col1" nameend="col9" align="center" valign="middle">* Coefficient of variation (C.V.): 18.4 %</entry></row></tbody></tgroup>
</table>
</tables><!-- EPO <DP n="29"> --></p>
<p id="p0094" num="0094">While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.</p><!-- EPO <DP n="30"> -->
<p id="p0095" num="0095"><img id="ib0004" file="imgb0004.tif" wi="153" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="31"> -->
<img id="ib0005" file="imgb0005.tif" wi="165" he="69" img-content="dna" img-format="tif"/></p>
</description><!-- EPO <DP n="32"> -->
<claims id="claims01" lang="en">
<claim id="c-en-0001" num="0001">
<claim-text>A <i>Pseudomonas oleovorans</i> strain KBPF-004 (KCTC 10159BP) having a controlling activity against plant viral diseases.</claim-text></claim>
<claim id="c-en-0002" num="0002">
<claim-text>A culture of the <i>Pseudomonas oleovorans</i> strain of claim 1.</claim-text></claim>
<claim id="c-en-0003" num="0003">
<claim-text>A dried powder of the culture of claim 2.</claim-text></claim>
<claim id="c-en-0004" num="0004">
<claim-text>The dried powder of claim 3, wherein the dried powder is prepared by freeze drying or spray drying.</claim-text></claim>
<claim id="c-en-0005" num="0005">
<claim-text>A microbial agent for controlling plant viral diseases comprising <i>Pseudomonas oleovorans</i> strain KBPF-004 (KCTC 10159BP), a culture thereof, or a dried powder of the culture as an active ingredient.</claim-text></claim>
<claim id="c-en-0006" num="0006">
<claim-text>The microbial agent of claim 5, which comprises 2.5 to 70% by weight of the <i>Pseudomonas oleovorans</i> strain, a culture thereof, or a dried powder of the culture; 2 to 30% by weight of a surfactant; and a residual amount of a carrier.</claim-text></claim>
<claim id="c-en-0007" num="0007">
<claim-text>The microbial agent of claim 6, wherein the surfactant is an anionic surfactant, nonionic surfactant, or a mixture thereof.</claim-text></claim>
<claim id="c-en-0008" num="0008">
<claim-text>The microbial agent of claim 6, wherein the carrier is selected from the group consisting of bentonite, talc, clay, kaolin, calcium carbonate, silica, pumice stone, diatomaceous earth, acidic white bole, zeolite, perlite, white carbon, ammonium sulfate, urea, glucose, dextrin, water, and a mixture thereof.</claim-text></claim>
<claim id="c-en-0009" num="0009">
<claim-text>The microbial agent of claim 5, which is in a form selected from the group consisting of wettable powders (WP), water dispersible granules (WG),<!-- EPO <DP n="33"> --> suspension concentrates (SC), granules, aqueous suspensions (AS), soluble powders (SP), water soluble granules (SG) and capsules.</claim-text></claim>
<claim id="c-en-0010" num="0010">
<claim-text>The microbial agent of claim 5, wherein the plant viral disease is caused by a plant virus group selected from the group consisting of Allexivirus, Alfamovirus, Ampelovirus, Bymovirus, Begomovirus, Capillovirus, Carlavirus, Carmovirus, Caulimovirus, Closterovirus, Comovirus, Cucumovirus, Crinivirus, Cytorhabdovirus, Fabavirus, Flexiviridae, Foveavirus, Furovirus, Geminivirus, Hordeivirus, Ilarvirus, Luteovirus, Maculavirus, Nepovirus, Potexvirus, Potyvirus, Phytoreovirus, Polerovirus, Pomovirus, Sadwavirus, Taastrupvirus, Tenuivirus, Tobamovirus, Tobravirus, Tombusvirus, Tospovirus, Trichovirus, and a combination thereof.</claim-text></claim>
</claims>
<drawings id="draw" lang="en">
<figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="164" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="34"> -->
<figure id="f0002" num="2,3"><img id="if0002" file="imgf0002.tif" wi="131" he="233" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="35"> -->
<figure id="f0003" num="4"><img id="if0003" file="imgf0003.tif" wi="165" he="108" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="36"> -->
<figure id="f0004" num="5,6"><img id="if0004" file="imgf0004.tif" wi="151" he="216" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="37"> -->
<figure id="f0005" num="7"><img id="if0005" file="imgf0005.tif" wi="161" he="126" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="38"> -->
<figure id="f0006" num="8A,8B,9"><img id="if0006" file="imgf0006.tif" wi="147" he="226" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="39"> -->
<figure id="f0007" num="10A,10B"><img id="if0007" file="imgf0007.tif" wi="109" he="174" img-content="drawing" img-format="tif"/></figure>
</drawings>
<ep-reference-list id="ref-list">
<heading id="ref-h0001"><b>REFERENCES CITED IN THE DESCRIPTION</b></heading>
<p id="ref-p0001" num=""><i>This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.</i></p>
<heading id="ref-h0002"><b>Non-patent literature cited in the description</b></heading>
<p id="ref-p0002" num="">
<ul id="ref-ul0001" list-style="bullet">
<li><nplcit id="ref-ncit0001" npl-type="s"><article><author><name>Fitchen, J. H.</name></author><author><name>Beachy, R. N.</name></author><atl/><serial><sertitle>Annu. Rev. Microbiol.</sertitle><pubdate><sdate>19930000</sdate><edate/></pubdate><vid>47</vid></serial><location><pp><ppf>739</ppf><ppl>763</ppl></pp></location></article></nplcit><crossref idref="ncit0001">[0004]</crossref></li>
<li><nplcit id="ref-ncit0002" npl-type="s"><article><author><name>Thompson JD et al.</name></author><atl/><serial><sertitle>Nuc. Acid. Res.</sertitle><pubdate><sdate>19970000</sdate><edate/></pubdate><vid>25</vid></serial><location><pp><ppf>4876</ppf><ppl>82</ppl></pp></location></article></nplcit><crossref idref="ncit0002">[0011]</crossref><crossref idref="ncit0003">[0043]</crossref></li>
<li><nplcit id="ref-ncit0003" npl-type="s"><article><author><name>Kim et al.</name></author><atl/><serial><sertitle>Plant Pathol. J.</sertitle><pubdate><sdate>20040000</sdate><edate/></pubdate><vid>20</vid><ino>4</ino></serial><location><pp><ppf>293</ppf><ppl>296</ppl></pp></location></article></nplcit><crossref idref="ncit0004">[0045]</crossref></li>
<li><nplcit id="ref-ncit0004" npl-type="s"><article><author><name>Choi et al.</name></author><atl/><serial><sertitle>Plant Pathol, J.</sertitle><pubdate><sdate>19980000</sdate><edate/></pubdate><vid>14</vid></serial><location><pp><ppf>7</ppf><ppl>12</ppl></pp></location></article></nplcit><crossref idref="ncit0005">[0069]</crossref></li>
<li><nplcit id="ref-ncit0005" npl-type="b"><article><atl/><book><author><name>Yoon</name></author><book-title>Doctoral Thesis</book-title><imprint><name>Seoul Women's Univ.</name><pubdate>20030000</pubdate></imprint><location><pp><ppf>166</ppf><ppl/></pp></location></book></article></nplcit><crossref idref="ncit0006">[0069]</crossref></li>
<li><nplcit id="ref-ncit0006" npl-type="s"><article><author><name>Clark et al.</name></author><atl/><serial><sertitle>J. Gen. virol.</sertitle><pubdate><sdate>19770000</sdate><edate/></pubdate><vid>34</vid></serial><location><pp><ppf>475</ppf><ppl>483</ppl></pp></location></article></nplcit><crossref idref="ncit0007">[0073]</crossref></li>
</ul></p>
</ep-reference-list>
</ep-patent-document>
